Clinical Trials Directory

Trials / Unknown

UnknownNCT03767673

Cardiorespiratory Performance and Pulmonary Microbiome in Patients After Repair of Esophageal Atresia

Examination of the Cardiorespiratory Performance Capacity and Pulmonary Microbiome in Patients Following Surgical Repair of Esophageal Atresia

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
50 (estimated)
Sponsor
Medical University of Graz · Academic / Other
Sex
All
Age
12 Years
Healthy volunteers
Accepted

Summary

The majority of the clinical research on esophageal atresia focuses on the upper gastrointestinal tract. However, the trachea and the lung are also affected in many of these children, so that a lifelong pulmonary impairment may result. The importance of respiratory function in the context of follow-up of these patients has therefore been increasingly recognized in recent years. Scientific work has shown significantly, that patients following esophageal atresia repair develop respiratory symptoms more frequently than the normal population. Mild impairment of the pulmonary function in adolescence and adulthood was demonstrated in some studies, but to date, there is no exact idea about the relationship between early childhood disease progression and later pulmonary impairment. Only a few scientific papers have dealt with the effect of impaired pulmonary function on the physical capacity of these adolescents and adults. Most of these studies show small case numbers, inconclusive stress tests, and divergent results. The aim of this prospective study is to investigate the cardiopulmonary performance capacity and the pulmonary microbiome of adolescent and adult patients with corrected esophageal atresia and to compare the results with a control group. Another focus of the investigators is on the composition of the pulmonary microbiome of the participants. Changes of the pulmonary microbiome and the influence on the cardio-pulmonary performance capacity have not yet been investigated. Furthermore, it should be investigated whether the treatment measures and a complicated disease course in the neonatal period have long-term effects on lung function, exercise capacity and composition of the microbiome in the lungs.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTInitial SpirometryDetermination of Vital Capacity by spirometry before (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
DIAGNOSTIC_TESTFinal SpirometryDetermination of Vital Capacity by spirometry after (within 30 minutes) spiroergometry. Measurements will be performed in both groups.
DIAGNOSTIC_TESTPulmonary microbiome (16S rDNA profiling)Harvesting of deep induced sputum and determination of the airway microbiome by 16S ribosomal RNA (rRNA) pyrosequencing. Evaluation of alpha and beta diversity and relative bacterial abundance at the genus level. Measurements will be performed in both groups (samples will be harvested within 30 minutes after spiroergometry).
DIAGNOSTIC_TESTMaximum oxygen uptakeDetermination of the maximum oxygen uptake (ml/kg/min) corrected for gender, age and body weight by bicycle spiroergometry. Measurements will be performed in both groups.
DIAGNOSTIC_TESTMaximum performanceDetermination of the maximum performance (W/kg) corrected for body weight by bicycle spiroergometry. Measurements will be performed in both groups.
DIAGNOSTIC_TESTweightDetermined by Kilogram on a medical weight scale
OTHERageDetermination of age by patient's Report and past medical history

Timeline

Start date
2017-08-10
Primary completion
2019-04-06
Completion
2019-09-02
First posted
2018-12-06
Last updated
2018-12-06

Locations

1 site across 1 country: Austria

Source: ClinicalTrials.gov record NCT03767673. Inclusion in this directory is not an endorsement.